Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response

Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response

Bibliographic Details
Main Authors:	Pablo Iglesias, Simone Ribero, Alicia Barreiro, Sebastian Podlipnik, Cristina Carrera, Josep Malvehy, Susana Puig
Format:	Article
Language:	English
Published:	Medical Journals Sweden 2018-11-01
Series:	Acta Dermato-Venereologica
Online Access:	https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3061

Similar Items

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec
by: Jonathan T. Blackmon, et al.
Published: (2017-07-01)

Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec
by: Erin M. McClure, BS, et al.
Published: (2023-02-01)

Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma
by: Kate E. Beekman, BS, et al.
Published: (2023-03-01)

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
by: Pier Francesco Ferrucci, et al.
Published: (2021-03-01)

Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC)
by: Jennifer Gardner, et al.
Published: (2018-07-01)

Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
by: Jennifer Gardner, et al.
Published: (2022-10-01)

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection
by: Leonid Shmuylovich, MD, PhD, et al.
Published: (2022-11-01)

Talimogene laherparepvec: First in class oncolytic virotherapy
by: Robert M. Conry, et al.
Published: (2018-04-01)

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanomaResearch in context
by: Robert H.I. Andtbacka, et al.
Published: (2019-09-01)

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class
by: Howard L. Kaufman, et al.
Published: (2022-02-01)

Locoregional melanoma metastases resistant to PD-1 inhibitor therapy treated with intralesional talimogene laherparepvec
by: Matthew M. Wallace, MD, et al.
Published: (2024-01-01)

Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec
by: Yonglu Che, MD, PhD, et al.
Published: (2024-04-01)

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec
by: Neha Singh, BS, et al.
Published: (2023-06-01)

Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Published: (2021-10-01)

Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy
by: Tiantian Zhang, et al.
Published: (2023-01-01)

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab
by: David M. Miller, et al.
Published: (2018-11-01)

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
by: Dirk Schadendorf, et al.
Published: (2021-03-01)

Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec
by: Jamie Lebhar, BME, et al.
Published: (2023-10-01)

Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report
by: Anne Fröhlich, et al.
Published: (2020-05-01)

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition
by: Zoë Blake, et al.
Published: (2018-04-01)

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
by: Lillian Sun, et al.
Published: (2018-05-01)

Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient
by: Max Miller, et al.
Published: (2023-06-01)

409 A phase i trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO)
by: John Stewart, et al.
Published: (2020-11-01)

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
by: Jens Tijtgat, et al.
Published: (2021-10-01)

Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient
by: Kelsey E. Hirotsu, MD, et al.
Published: (2021-07-01)

Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T‐VEC) a first‐in‐class oncolytic viral therapy in patients with advanced melanoma
by: Malidi Ahamadi, et al.
Published: (2023-02-01)

Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): Subgroup analysis of the phase III OPTiM study
by: Middleton, M, et al.
Published: (2019)

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
by: Celeste Lebbe, et al.
Published: (2023-05-01)

Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence
by: Sümeyre Seda Ertekin, et al.
Published: (2021-07-01)

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
by: Robert H. I. Andtbacka, et al.
Published: (2019-06-01)

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)
by: Sant P. Chawla, et al.
Published: (2023-05-01)

Reflectance Confocal Microscopy and Electrical Impedance Spectroscopy in the Early Detection of Melanoma in Changing Lesions during Long-term Follow-up of Very High-risk Patients
by: Marion Chavez-Bourgeois, et al.
Published: (2022-07-01)

Diagnostic Accuracy of Image-guided Biopsies for Diagnosis of Metastatic Melanoma in a Real-life Setting
by: Laura Serra-García, et al.
Published: (2022-12-01)

Microblotches on Dermoscopy of Melanocytic Lesions are Associated with Melanoma: A Cross-sectional Study
by: Vania Lukoviek, et al.
Published: (2020-04-01)

A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors
by: Lucas Moreno, et al.
Published: (2023-05-01)

Lichenoid keratosis simulating melanoma: A case report.
by: Leire Barrutia, et al.
Published: (2022-10-01)

Pseudonits or Hair Casts
by: Vania Lukoviek, et al.
Published: (2020-10-01)

Topographical and Chronological Analysis of Thin Cutaneous Melanoma’s Progressions: A Multicentric Study
by: Emmanouil Chousakos, et al.
Published: (2023-08-01)

Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
by: Bart Neyns, et al.
Published: (2022-09-01)

Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival
by: Lorena Villa-Crespo, et al.
Published: (2022-02-01)